Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive
dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).